Related Experiment Video
Updated: Jul 21, 2025
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.1K
Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect
Abdul Majid1,2, Fasilat Oluwakemi Hassan1,2, Md Monirul Hoque1,2
1Department of Physiology, College of Medicine, The University of Tennessee Health Science Center, Translational Research Building, Room 318H, 71 S. Manassas, Memphis, TN 38163, USA.
Journal of Cardiovascular Development and Disease
|July 28, 2023
Summary
Bioactive compounds show promise in treating cardiac fibrosis, a key factor in heart failure. Their anti-inflammatory and antioxidant properties may reduce or prevent this condition.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biochemistry
Background:
- Cardiac fibrosis, excessive heart matrix deposition, drives heart failure progression.
- Current treatments for myocardial fibrosis remain limited.
- Bioactive compounds offer potential antifibrotic therapeutic strategies.
Purpose of the Study:
- To review cardiac fibrosis mechanisms and current treatment limitations.
- To explore bioactive compounds as antifibrotic agents.
- To highlight therapeutic potential for preventing/reducing cardiac fibrosis.
Main Methods:
- Comprehensive literature review on cardiac fibrosis.
- Analysis of molecular mechanisms of fibrogenesis.
- Evaluation of bioactive compounds' antifibrotic properties.
Main Results:
- Bioactive compounds possess anti-inflammatory and antioxidant effects.
- These compounds modulate extracellular matrix production and fibroblast differentiation.
- Potential to inhibit or promote breakdown of fibrotic components.
Conclusions:
- Bioactive compounds represent a promising therapeutic avenue for cardiac fibrosis.
- Targeting fibrogenic processes with these compounds may prevent heart failure.
- Further investigation is warranted for clinical application in cardiac fibrosis treatment.
More Related Videos
Related Concept Videos
01:21Myocarditis I: Introduction
10
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
10
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:26Heart Failure Drugs: Inotropic Agents
626
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:29Pathophysiology of Cardiac Performance
706
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
706